Cancer

Elderly Immunotherapy

First Opinion

We need more answers about immunotherapy for the elderly

By Ankur Parikh

Pancreatic cancer cells

Health

Muscle and fat loss may offer clues to pancreatic cancer’s deadly ways

advertisement

Wong Maye-E/AP

First Opinion

Barriers to genomic testing get in the way of precision medicine

By Chadi Nabhan

advertisement

First Opinion

New Gardasil ad campaign gets it (mostly) right. It shouldn’t have taken a decade

By Ashley Andreou

Biotech

China just approved its first cancer immunotherapy drug. Here’s what’s next in the pipeline

By Rebecca Robbins

In the Lab

A serious new hurdle for CRISPR: Edited cells might cause cancer, two studies find

By Sharon Begley

Pharmalot

What Trump pushback? Bayer takes hefty price hikes on two cancer drugs in just six months

By Ed Silverman

advertisement

Health

As CAR-T treatments advance, Washington grapples with ideas for how to pay for them

By Erin Mershon

advertisement

Health

How a U.S. postal stamp helped fund a pivotal study on breast cancer

By Associated Press

Breast Cancer Cells

In the Lab

From one breast cancer patient’s turnaround, clues to a new immunotherapy

By Sharon Begley

Pharmalot

Pharmalittle: PBM mail order pharmacies hurting cancer patients; colon cancer drugs cost twice in U.S. vs Canada

By Ed Silverman

Business

After the ASCO weekend, cancer drug stocks are moving. Here are your winners and losers

By Adam Feuerstein

Health

A new cancer care dilemma: Patients want immunotherapy even when evidence is lacking

Health

Many breast cancer patients can skip chemo, big study finds

By Associated Press

A digital representation of the human genome.

Biotech

Loxo Oncology shows high tumor response rates with second genetically targeted cancer drug

By Adam Feuerstein

ASCO Liquid Biopsy

Biotech

Grail’s cancer blood test shows ‘proof of principle,’ but challenges remain

By Sharon Begley

Human Colon Cancer Cells

Health

Cancer group says colon screening should start at 45, not 50

By Associated Press

Biotech

Research in mice may explain CAR-T therapy’s toxic side effects — and how to block them

By Meghana Keshavan

Pharmalot

Pharmalittle: Did White House official violate ethics rules? Purdue execs knew about OxyContin abuse

By Ed Silverman

Multiple Myeloma 01

Health

Once quickly lethal and still humbling, multiple myeloma may be in a ‘golden age’ of treatment

By Karen Weintraub

Pharmalot

Pharmalittle: Mylan pressures Pfizer to fix EpiPen production problems; AstraZeneca cancer drug hits goal

By Ed Silverman

Pharmalot

Spending on cancer drugs in the U.S. has doubled in the last five years, and will double again

By Ed Silverman

Conference Hype

First Opinion

Why was Theranos so believable? Medicine needs to look in the mirror

By Michael J. Joyner

Norman Sharpless

Health

The head of the National Cancer Institute on hopes for AI, the future of precision medicine, and big data

DNA Helix

First Opinion

A focus on cost instead of value threatens the future of personalized medicine

By Edward Abrahams

Pharmalot

Pharmalittle: Insys execs claim feds made ‘ugly insinuations’; just how many Pfizer drugs are in short supply?

By Ed Silverman

First Opinion

For cancer patients, Trump’s drug pricing proposal falls short

By Steven Kalkanis and Jonathan Trent

First Opinion

An opioid shortage? It’s real and could harm cancer patients

By Tara Soumerai

CAR-T Conference

In the Lab

For cancer immunotherapies, a radioactive crystal ball might foretell success or failure

By Sharon Begley